Effect of Nutritional Supplement Momordica Charantia in Type 2 Diabetes Mellitus

Effectiveness And Safety of Nutritional Supplement Momordica Charantia in Type 2 Diabetes Mellitus:Randomised Open Label Study- PG Dissertation - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/06/068929

Enrollment

Registered

2024-06-14

Start date

Unknown

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Metformin 500-1500mg/day + Sulfonylureas (Glimepiride 2-6 mg/day) + Tablet.Karavellaka(Momordica Charantia) 250mg: Participants in the group A will be receiving Metformin 500-1500mg/day

Eligibility

Inclusion criteria

Inclusion criteria: Patient with type 2 diabetes mellitus Patients receiving two drugs (Sulfonylureas (Glimepiride) + Metformin) for a minimum period of 12 weeks Patients with HbA1c 6.5 To 8%

Exclusion criteria

Exclusion criteria: Patients with type 2 diabetes mellitus receiving insulin Patients with liver dysfunction Patients who are on treatment with either steroids or immunosuppressive agents Pregnancy or Lactation Patients with renal impairment

Design outcomes

Primary

Measure	Time frame
To Assess the Effect of Momordica Charantia (Mc) Supplement on Blood Sugar and HbA1c In Type 2 Diabetic Patients Receiving Oral Antidiabetic Medications To assess adverse effects of Momordica charantia supplement using WHO causality assessment scaleTimepoint: Blood sugar,HbA1c and adverse effects at 0(baseline),Week 6,Week 12	—

Secondary

Measure	Time frame
NilTimepoint: Nil	—

Countries

India

Contacts

Public ContactSarala N

R L Jalappa Hospital & Research Center, Sri Devaraj Urs Medical College

saralan@sduaher.ac.in9845750165

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026